Viral pneumonias remain a global health threat necessitating novel strategies to prevent 18 and treat these lower respiratory tract infections. We have reported that mice treated 19 with a combination of inhaled Toll-like receptor (TLR) 2/6 and TLR 9 agonists (Pam2-20 2 ODN) are broadly protected against respiratory pathogens. Although a single inhalation 21 of Pam-ODN prevents acute morbidity and chronic complications associated with viral 22 pneumonias, the mechanisms underlying this protection remain incompletely elucidated.
Introduction 37
Viruses are the most frequent cause of community acquired pneumonia in children and 38 adults 1 . Respiratory viral infections result in significant morbidity and mortality in 39 vulnerable subjects, exerting a tremendous health care burden [1] [2] [3] [4] . In addition to causing 40 acute disease, respiratory virus infections are often complicated by chronic lung 41 pathologies, such as asthma induction, progression and exacerbation [5] [6] [7] . Therefore, Pam2-ODN attenuates SeV-induced lymphocytic lung inflammation. 126 To explore this hypothesis, the host leukocyte response to SeV infection was 127 characterized. Differential Giemsa staining of bronchoalveolar lavage (BAL) cells 128 revealed increased neutrophils on days 2 to 5 and increased macrophages on days 5 to rapid rise in neutrophils that was resolved within 5 days (Fig 3a, dashed line) 21 . The 132 neutrophil response to SeV challenge was modestly increased among mice pretreated 133 with Pam2-ODN ( Fig. 3a , left panel, solid dark line). Pam2-ODN-treated, SeV-134 challenged mice showed almost no difference in macrophages compared to PBS-135 treated, SeV-challenged mice (Fig. 3a , middle panel, solid dark line). A rise in 136 lymphocytes was observed on days 8 to 11 in PBS-treated, SeV-challenged mice ( Fig.   137 3a, right panel, solid grey line), temporally corresponding with peak mortality. However, 138 Pam2-ODN treated, SeV-challenged mice displayed significantly reduced lymphocyte 139 numbers at every time point assessed (Fig 3a, right panel, solid dark line). The gating 140 strategy for lymphocyte subsets by flow cytometry is shown in Supplementary Fig. 1 . A 141 modest reduction in CD4 + T cells was observed in Pam2-ODN-treated, SeV-challenged 142 mice compared to PBS-treated, SeV-challenged mice ( Supplementary Fig. 2 ). We also 143 found the percentage of CD19 + B220 + B cells reduced after SeV infection in comparison 144 to Pam2-ODN treated and uninfected mice ( Supplementary Fig. 2 ), as has been seen 145 with other viral models 22, 23 . However, the biggest difference between groups was in 146 CD8 + T cells, with Pam2-ODN-treated, SeV-challenged mice displaying a significantly 147 lower number and percentage of CD8 + T cells than PBS treated, SeV-challenged mice 148 (Fig. 3b, c) . Since the greatest difference after Pam2-ODN treatment was in CD8 + T cell 149 levels and there was a tight correlation between peak mortality and the increase in lung 150 CD8 + T cells on days 8 to 11, we investigated the role of CD8 + T cells in SeV-induced 151 mortality. To assess the role of CD8 + T cells in SeV defense and host mortality, mouse CD8 + T 162 cells were depleted prior to SeV challenge ( Fig. 4a, Supplementary Fig. 3 ). This 163 depletion resulted in significantly reduced survival of SeV infection (Fig. 4b ). The nearly 164 90% mortality in SeV challenged CD8 + T cell depleted mice ( Fig. 4b ) was associated 165 with impaired viral clearance ( Fig. 4c, Supplementary Fig. 4 ). This was not surprising, 166 given the known role of CD8 + T cells in virus clearance 24-28 . However, Pam2-ODN 167 treatment still significantly enhanced survival of SeV challenge, even in the absence of 168 CD8 + T cells (Fig. 4b ). This protection was again associated with reduced SeV burden 169 compared to CD8 + T cell-depleted, SeV-challenged mice without Pam2-ODN treatment 170 ( Fig. 4c, Supplementary Fig. 4 ). These results were congruent with our previous studies 171 showing Pam2-ODN inducible resistance against bacterial pneumonia despite the lack 172 of mature lymphocytes (Rag1 -/-) 12 .
173
As it appeared likely that CD8 + T cells contributed both beneficial (antiviral) and 174 deleterious (immunopathologic) effects, we depleted the CD8 + T cells on day 8 --after 175 9 virus begin to clear but before peak mortality ( Fig. 4d ). Interestingly, mice depleted of 176 CD8 + T cells on day 8 displayed enhanced survival of SeV challenge compared to mice 177 with intact CD8 + T cells ( Fig. 4e ). Depletion of CD8 + T cells was confirmed by flow 178 cytometry in disaggregated lung cells 10 days after SeV challenge ( Fig. 4f , 179 Supplementary Fig. 3 ). We also assessed lung injury by H&E staining of lung tissue 10 180 days after SeV challenge and found increased inflammation and epithelial cell damage 181 in undepleted mice compared to CD8 + T cell-depleted mice (Fig. 4g ). This supported 182 our hypothesis that, while CD8 + T cells confer anti-viral immunity, they also contribute to 183 fatal SeV-induced immunopathology. suggest that the surge in CD8 + T cells within the lungs after most virus has been 262 cleared causes physiologic impairment via lung injury and cell death (Fig 4d-g) . effect. Exploring this, we found no difference in number of SeV particles attached to the 286 cells between PBS and Pam2-ODN treatment (Fig 5a-d) . However, attached virus 287 14 particles that were from Pam2-ODN treated cells retain less infective capacity when 288 added to naïve epithelial cells, revealing pre-internalization virus inactivation by Pam2-289 ODN treatment (Fig 5e, f) .
290
Knowing that Pam2-ODN inducible resistance required ROS production to protect 291 against influenza 16 , we studied the role of ROS in Pam2-ODN-mediated reduction in in SeV pneumonia (Fig 6a, b , e, f). Further, ROS inhibition also led to loss of Pam2-296 ODN-inducible in vitro inactivation of SeV prior to epithelial internalization (Fig. 6c) , 297 demonstrating for the first time that epithelial ROS directly contribute to virus 298 inactivation.
299
Production of ROS as a microbicidal mechanism has been widely reported in 300 phagocytic cells [36] [37] [38] . However, this mechanism has not been extensively studied in non-301 phagocytic cells 39 , where it apparently acts predominantly extracellularly rather than 302 intracellularly as in phagocytes. (Fig. 5f, g) . Induction of a sustained microbicidal state 303 through lung epithelial reprogramming can potentially explain the broad protection seen 304 against multiple pathogens [12] [13] [14] 21, 34, 40 . These findings of viral inactivation by epithelial 305 ROS production reveal an essential component of inducible epithelial resistance.
306
Taken together, these findings provide mechanistic insights into the role of the lung 307 epithelium in induction of anti-viral responses and prevention of host immunopathology 308 that may inform future therapeutics to protect vulnerable populations.
Methods

310
Mice: All in vivo experiments were performed using 6 to 10-week-old C57BL/6J mice of were then stained following the Click-iT EdU Imaging Kit protocol for EdU (Abcam,) 370 followed by staining with DAPI for 30 min at room temperature. Images were collected 371 using Olympus BX 60 microscope using identical parameters for all conditions. Some 372 lung sections were subjected to antigen retrieval and then stained for Ki67 (1:1000; 
